Stock to Target: Aridis Pharmaceuticals Inc (NASDAQ: ARDS)

On Thursday, Aridis Pharmaceuticals Inc (NASDAQ: ARDS) stock gained 3.48% and closed at 5.95. The stock opened the session at $5.37 and touched its highest price point at $6.4. Its recent trading capacity is 10,072 shares versus to its average trading volume of 17152 shares. The company’s stock’s lowest price point for the session stood at $5.37.

Aridis Pharmaceuticals, Inc. (ARDS) reported recently that it has designated Paul Mendelman, MD as interim Chief Medical Officer (CMO). Dr. Mendelman replaces Dr. Wolfgang Dummer who has departed the company for personal reasons.

“It is a pleasure to welcome Dr. Mendelman, a recognized leader in the development of new treatments for infectious diseases to the Aridis team. His expertise comes at a critical juncture for the company given we are advancing multiple clinical programs, including our lead Phase 3 antibody program, AR-301, which can benefit from additional infectious disease expertise particularly in critical care (ICU) settings,” commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.

Dr. Mendelman brings to Aridis a prolific career in infectious diseases across industry and academia spanning over 30 years with board certification in pediatrics and pediatric infectious diseases. He has held senior clinical development positions at leading companies such as Takeda Vaccines (Vice President, Medical), MedImmune (Vice President & Therapeutic Area Leader, Clinical Development), and Merck (Director, Clinical Research Infectious Diseases). From 1996 to 2005, he managed the clinical development group for FluMist®, the live attenuated intranasal influenza vaccine, licensed initially in the U.S. for the 2003-04 season.

Return on assets ratio of the Company was -109.00% and return on equity ratio was -136.60% while its return on investment ratio was -91.70%. The stock as of last trading session moved 10.59% up from its 52-week low and was -54.23% behind its 52-week high.  ARDS price switched up -16.56% 20-Days Simple Moving Average, dropped -29.91% from 50-Days Simple Moving Average and fell -35.68% from 200 Days Simple Moving Average.

Leave a Reply

Your email address will not be published. Required fields are marked *